Seminário: "Doxil, the first FDA approved nano-drug: lessons learned"

Doxil, the first FDA approved nano-drug: lessons learned


a ser apresentado pelo
Professor Yechezkel Barenholz
Universidade Hebraica de Jerusalém


22 de outubro às 16:00 hs
Anfiteatro Vermelho, Bloco 6 Superior
Instituto de Química da USP



A visita do Prof. Barenholz está sendo patrocinada pelos
Amigos da Universidade Hebraica de Jerusalém


Seguem abaixo informações sobre o currículo e a pesquisa do Prof. Barenholz


Yechezkel (Chezy) Barenholz is Professor of Biochemistry and Daniel G. Miller Professor in Cancer Research. He is the head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry, Hebrew University–Hadassah Medical School, Jerusalem. His laboratory is also part of the Center for Nanoscience and Nanotechnology of the Hebrew University.  

During his Ph.D. Professor Barenholz studied at the Animal Research Council Institute at Babraham, Cambridge, under the supervision of A.D. Bangham, considered the "father of liposomes". He has been on staff at the Hebrew University since 1974. He was also on staff at the University of Virginia, Charlottesville, and remains a Visiting Professor there until today. He was Visiting Professor at the University of Utrecht, Kyoto University, La Sapienza University, Shanghai Jiaotong University, and Kings College, University of London.

Professor Barenholz´s projects focus on both basic and applied research (Liposomes and Lipid Assemblies, From Nanotechnology and Nanomedicine to Approved Nano-Drugs). The research is developed by combining nano-technology and nano-medicine with various aspects of biophysics and biology to develop liposome- and nanoliposome-based drugs (nano-drugs) for therapeutic applications. These carriers are loaded with antigens (as vaccines); nucleic acids (especially siRNA) for gene manipulation in vitro, in tissue culture, and in vivo); low molecular weight drugs (anticancer and anti-inflammatory). These studies led to the development of DoxilTM, the first liposomal drug and nanomedicine approved by the FDA.

Professor Barenholz is the author of over 330 publications, co-editor of two special issues of Chemistry and Physics of Lipids and of the 4-volume Handbook of Nonmedical Applications of Liposomes. He was Executive Editor of Progress in Lipid Research and is on the editorial boards of Chemistry and Physics of Lipids, Journal of Liposome Research, Cellular & Molecular Biology Letters, and International Journal of Oncology. Professor Barenholz is co-inventor of over 60 patents. He was awarded a number of prestigious prizes for his contributions to medical application of liposomes and to liposome science and technology, including the Alec D. Bangham Award for “Lifelong achievement resulting in fundamental and sustained impact on the advancement of liposome science and technology”. In 2003, he established the Barenholz Prize for Applied Research to encourage doctoral students to pursue excellence and innovation in applied research.